TrivarX Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

TrivarX has a total shareholder equity of A$9.9M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$11.1M and A$1.2M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$848.10k
Aandelen	AU$9.89m
Totaal verplichtingen	AU$1.17m
Totaal activa	AU$11.07m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: TRI's short term assets (A$915.2K) do not cover its short term liabilities (A$1.2M).

Langlopende schulden: TRI has no long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: TRI is debt free.

Schuld verminderen: TRI has no debt compared to 5 years ago when its debt to equity ratio was 32%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: TRI has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: TRI has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.5% each year.

TrivarX Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven